Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) EBIAT (2016 - 2025)

Catalyst Pharmaceuticals' EBIAT history spans 16 years, with the latest figure at $52.7 million for Q4 2025.

  • For Q4 2025, EBIAT fell 5.79% year-over-year to $52.7 million; the TTM value through Dec 2025 reached $214.3 million, up 30.78%, while the annual FY2025 figure was $214.3 million, 30.78% up from the prior year.
  • EBIAT reached $52.7 million in Q4 2025 per CPRX's latest filing, roughly flat from $52.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $56.7 million in Q1 2025 to a low of -$30.8 million in Q3 2023.
  • Average EBIAT over 5 years is $28.6 million, with a median of $27.5 million recorded in 2022.
  • Peak YoY movement for EBIAT: plummeted 235.24% in 2023, then skyrocketed 242.65% in 2024.
  • A 5-year view of EBIAT shows it stood at $9.3 million in 2021, then surged by 173.62% to $25.5 million in 2022, then surged by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then decreased by 5.79% to $52.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EBIAT are $52.7 million (Q4 2025), $52.8 million (Q3 2025), and $52.1 million (Q2 2025).